DOI: 10.1002/ame2.12264
The role of prolactin/vasoinhibins in cardiovascular diseases
Hui Zhao1
Sugang Gong2
Yongcong Shi3
Cijun Luo2
Hongling Qiu2
Jing He2
Yuanyuan Sun2
Yuxia Huang2
Shang Wang2
Yuqing Miao4
Wenhui Wu2
1.School of Materials and Chemistry&Institute of Bismuth and Rhenium,University of Shanghai for Science and Technology,Shanghai,China;Department of Cardio-Pulmonary Circulation,School of Medicine,Shanghai Pulmonary Hospital,Tongji University,Shanghai,China2.Department of Cardio-Pulmonary Circulation,School of Medicine,Shanghai Pulmonary Hospital,Tongji University,Shanghai,China3.Respiratory Medicine,Dongchuan District People's Hospital,Kunming,China4.School of Materials and Chemistry&Institute of Bismuth and Rhenium,University of Shanghai for Science and Technology,Shanghai,China
摘要：Prolactin(PRL)is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary.There are two main isoforms of PRL:23-kDa PRL(named full-length PRL)and vasoinhibins(including 5.6-18 kDa fragments).Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization,including endothelial cell proliferation and migration,protease production,and apoptosis.However,their effects on vascular function and cardiovascular diseases are different or even contrary.In addition to the structure,secretion regulation,and signal transduction of PRL/vasoinhibins,this re-view focuses on the pathological mechanism and clinical significance of PRL/vasoin-hibins in cardiovascular diseases.
机标关键词：rolecardiovasculardiseasesprolactinvasoinhibins
论文发表日期：2023-04-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：11( 81-91 )
英文信息